{"mainPropery":{"diseaseId":3230,"diseaseName":"Metachromatic leukodystrophy","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/3230/metachromatic-leukodystrophy","synonyms":["Leukodystrophy metachromatic","Metachromatic leukoencephalopathy","MLD","Sulfatide lipidosis","Arylsulfatase A deficiency","Cerebral sclerosis diffuse metachromatic form","Cerebroside sulfatase deficiency","ARSA deficiency"],"synonyms-with-source":[{"name":"Leukodystrophy metachromatic"},{"name":"Metachromatic leukoencephalopathy"},{"name":"MLD"},{"name":"Sulfatide lipidosis"},{"name":"Arylsulfatase A deficiency"},{"name":"Cerebral sclerosis diffuse metachromatic form"},{"name":"Cerebroside sulfatase deficiency"},{"name":"ARSA deficiency"}],"identifiers":[{"identifierType":"OMIM","identifierId":"250100"},{"identifierType":"ORPHANET","identifierId":"512"}]},"diseaseCategories":[{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"}],"organizations":[{"resourceID":195,"resourceName":"United Leukodystrophy Foundation","abbreviation":"ULF","address1":"224 North Second Street","address2":"Suite 2","address3":"","address4":"","address5":"","city":"DeKalb","state":"IL","zip":"60115 ","country":"United States","phone":"+1-815-748-3211 ","tty":"","tollFree":"1-800-728-5483","fax":"+1-815-748-0844","email":"office@ulf.org","url":"https://ulf.org/","freeText":""},{"resourceID":692,"resourceName":"MLD Foundation","address1":"21345 Miles Drive","address2":"","address3":"","address4":"","address5":"","city":"West Linn","state":"OR","zip":"97068-2878","country":"United States","phone":"503-656-4808","tty":"","tollFree":"800-617-8387","fax":"503-212-0159","email":"info@mldfoundation.org","url":"http://mldfoundation.org/"},{"resourceID":2219,"resourceName":"Alex The Leukodystrophy Charity","abbreviation":"Alex TLC","address1":"45 Peckham High Street","address2":"","address3":"","address4":"","address5":"","city":"London","state":"","zip":"SE15 5EB","country":"United Kingdom","phone":" 020 7701 4388","tty":"","tollFree":"","fax":"","email":"info@alextlc.org","url":"https://www.alextlc.org","freeText":""},{"resourceID":3478,"resourceName":"European Association against Leukodystrophy","abbreviation":" ELA","address1":"2, rue Mi-les-Vignes","address2":"BP 61024 54521","address3":"Laxou Cedex","address4":"","address5":"","city":"","state":"","zip":"","country":"France","phone":"","tty":"","tollFree":"","fax":"","email":"http://ela-asso.com/en/contact-2/","url":"http://ela-asso.com/en/","freeText":""},{"resourceID":4248,"resourceName":"The Calliope Joy Foundation","abbreviation":"","address1":"PO Box 2866","address2":"","address3":"","address4":"","address5":"","city":"Bala Cynwyd","state":"PA","zip":"19004","country":"","phone":"610-664-1588","tty":"","tollFree":"","fax":"","email":"info@thecalliopejoyfoundation.org","url":"https://www.thecalliopejoyfoundation.org","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/250100' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=Metachromatic+leukodystrophy++%5Bti%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Metachromatic leukodystrophy. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Metachromatic+leukodystrophy%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Metachromatic leukodystrophy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=metachromaticleukodystrophy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Metachromatic leukodystrophy. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":267,"resourceId":1104,"resourceName":"American Society of Gene & Cell Therapy -Disease treatment","descriptionText":"The <a href='https://www.asgct.org/education' target='_blank'>American Society of Gene &amp; Cell Therapy</a> provides information on the treatment of genetic diseases.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":869,"resourceId":1575,"resourceName":"RDCRN - Lysosomal Disease Network","descriptionText":"The&nbsp;<a href='https://www.rarediseasesnetwork.org/ldn' target='_blank'>Lysosomal Disease Network</a>&nbsp;is a team of doctors, nurses, research coordinators, and research labs throughout the U.S., working together to improve the lives of people with this condition through research. The&nbsp;Lysosomal Disease Network&nbsp;has a registry for patients who wish to be contacted about clinical research opportunities.<br />","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0023522' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/212/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001205.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Metachromatic-Leukodystrophy-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/951840-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022235' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=512' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1130/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:250100' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Metachromatic leukodystrophy. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Metachromatic leukodystrophy:<br />\r\n<a href='https://www.chop.edu/research/myelin-disorders-biorepository-project' target='_blank'>Myelin Disorders Bioregistry Project</a><br /><a href='http://www.mldfoundation.org/registry.php' target='_blank'>Metachromatic Leukodystrophy Foundation Patient-Powered Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":4529,"questionText":"What is metachromatic leukodystrophy?","answerText":"<strong>Metachromatic leukodystrophy</strong> is an inherited condition characterized by the accumulation of fats called sulfatides in cells, especially cells of the nervous system. This accumulation results in progressive destruction of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002344.htm\" target=\"_blank\">white matter of the brain</a>, which consists of nerve fibers covered by <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/9682.htm\" target=\"_blank\">myelin</a>.&nbsp;Affected individuals experience progressive deterioration of <a href=\"http://www.cdc.gov/ncbddd/dd/ddmr.htm\" target=\"_blank\">intellectual functions</a> and motor skills, such as the ability to walk. They also develop loss of sensation in the extremities, <a href=\"http://www.nlm.nih.gov/medlineplus/urinaryincontinence.html\" target=\"_blank\">incontinence</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/paralysis.html\" target=\"_blank\">paralysis</a>, inability to speak, blindness, and hearing loss. Eventually they lose awareness of their surroundings and become unresponsive. This condition is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> pattern and is caused by mutations in the <em><a href=\"http://ghr.nlm.nih.gov/gene/ARSA\" target=\"_blank\">ARSA</a>&nbsp;</em>and <em><a href=\"http://ghr.nlm.nih.gov/gene/PSAP\" target=\"_blank\">PSAP</a></em> genes.[3493]<br />\r\n<br />","dateModified":"2014-09-19T00:00:00"},"basicQuestions":[{"questionId":6259,"questionText":"How is metachromatic leukodystrophy inherited?","answerText":"Metachromatic leukodystrophy is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner. This means that both copies of the disease-causing&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=_blank>gene</a> in each cell must have a&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutation</a> for an individual to be affected. Individuals inherit two copies of each gene - one copy from each parent. Typically, an individual is affected because they inherited a mutated copy of the gene from each parent. Individuals with one mutated copy of the gene (such as an unaffected parent of an affected individual) are referred to as carriers; carriers typically do not have any signs or symptoms of the condition.<br><br>When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) chance to have the condition, a 50% (1 in 2) chance to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.<br>","dateModified":"2012-06-28T09:40:00","resourceClassificationName":"Inheritance","references":[]},{"questionId":6261,"questionText":"Who might consider genetic carrier testing for a family history of metachromatic leukodystrophy?","answerText":"<p>If someone has a family history of metachromatic leukodystrophy (MLD)&nbsp;or someone is known to be a carrier&nbsp;for MLD, individuals who are biologically related to the affected individual or carrier are at risk to be a carrier. Generally speaking, the more closely related an individual is to the affected individual or carrier, the greater the chance for that person to be a carrier. Prior to genetic testing, the chance to be a <strong>carrier</strong> for some biological relatives of an affected individual are as follows:</p>\r\n<ul>\r\n<li>Parent of affected individual: assumed to be 100% (called an obligate carrier) \r\n<li>Unaffected sibling of affected individual: 2 in 3 (~66.6%) \r\n<li>Aunt or uncle of affected individual: 1 in 2 (50%) \r\n<li>First cousin of affected individual: 1 in 4 (25%)</li></ul>\r\n<p>If someone has carrier testing and is found to be negative (not a carrier), that person's children are typically assumed to be negative also.<br><br>More information about the use of genetic carrier testing is available on GeneTests' Web site and can be viewed by clicking <a href=\"http://www.ncbi.nlm.nih.gov/projects/GeneTests/static/concepts/primer/primerusesof.shtml#carrier\" target=_blank>here</a>.<br><br>Individuals who are interested in learning about genetic testing and about their specific risk to be a carrier should speak with a genetics professional.</p>","dateModified":"2012-06-28T10:57:00","resourceClassificationName":"Diagnosis","references":[]},{"questionId":6193,"questionText":"What is the prognosis for individuals with metachromatic leukodystrophy?","answerText":"The prognosis for metachromatic leukodystrophy (MLD) is poor.[5223] The late infantile&nbsp;form of the disorder, the most common type, usually appears in the second year of life. This form typically progresses over approximately 5 to 10 years.[5224] Most children with the infantile form die by age 5.[5223] The juvenile form, with onset between the age of 4 and adolescence, has a slower progression than the late infantile form and symptoms may develop over 10 to 20 years; death typically occurs 10 to 20 years following onset.[5223][5224] In the adult form, the first symptoms typically&nbsp;appear during the teenage years or later. This form may possibly progress over 20 to 30 years, although many individuals with the adult form die within 6 to 14 years following the onset of symptoms.[5223][5224] During the progression of this form there may be some periods of relative stability and other periods of more rapid decline.[5224]","dateModified":"2012-05-09T11:41:00","resourceClassificationName":"Prognosis","references":[{"referenceId":5223,"authors":"","articleTitle":"Metachromatic Leukodystrophy Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke (NINDS)","date":"June 22, 2018","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Metachromatic-Leukodystrophy-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5224,"authors":"","articleTitle":"Metachromatic leukodystrophy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"September 2007","url":"http://ghr.nlm.nih.gov/condition/metachromatic-leukodystrophy","dateAccessed":"2012-05-09T00:00:00"}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":6895,"relatedDiseaseName":"Leukodystrophy","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":7672,"relatedDiseaseName":"Sphingolipidosis","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":35669,"abbreviatedInquiry":"My 2 year old grandson has MLD. So both parents are carriers. I have three other children and 2 of them have one child each. All 3 of my other children are planning to have another child. Who in the family needs to be tested for the carrier gene for MLD? Does a child of a carrier automatically become a carrier as well? Will that carrier gene continue to be passed on and should all my family be tested?","caseQuestions":[{"questionId":6259,"questionText":"How is metachromatic leukodystrophy inherited?","answerText":"Metachromatic leukodystrophy is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner. This means that both copies of the disease-causing&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=_blank>gene</a> in each cell must have a&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutation</a> for an individual to be affected. Individuals inherit two copies of each gene - one copy from each parent. Typically, an individual is affected because they inherited a mutated copy of the gene from each parent. Individuals with one mutated copy of the gene (such as an unaffected parent of an affected individual) are referred to as carriers; carriers typically do not have any signs or symptoms of the condition.<br><br>When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) chance to have the condition, a 50% (1 in 2) chance to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.<br>","dateModified":"2012-06-28T09:40:00","resourceClassificationName":"Inheritance","references":[]},{"questionId":6260,"questionText":"Is someone is a carrier for metachromatic leukodystrophy, what are the chances for his/her siblings to be carriers?","answerText":"Each sibling of a carrier for&nbsp;metachromatic leukodystrophy (MLD) has a 50% chance to also be a carrier. A carrier for MLD has one mutated copy of the disease-causing gene in each cell (as well as one normal copy). Typically, a carrier will have inherited the mutated copy from a carrier parent. A carrier parent, who also has one mutated copy and one normal copy of the gene, will randomly pass one of these copies on to each child. Therefore, at conception, each child of a carrier has a 50% (1 in 2) chance inherit the mutated copy and be a carrier, and a 50% chance to inherit the normal copy and not be a carrier.","dateModified":"2012-06-28T10:05:00","references":[]},{"questionId":6261,"questionText":"Who might consider genetic carrier testing for a family history of metachromatic leukodystrophy?","answerText":"<p>If someone has a family history of metachromatic leukodystrophy (MLD)&nbsp;or someone is known to be a carrier&nbsp;for MLD, individuals who are biologically related to the affected individual or carrier are at risk to be a carrier. Generally speaking, the more closely related an individual is to the affected individual or carrier, the greater the chance for that person to be a carrier. Prior to genetic testing, the chance to be a <strong>carrier</strong> for some biological relatives of an affected individual are as follows:</p>\r\n<ul>\r\n<li>Parent of affected individual: assumed to be 100% (called an obligate carrier) \r\n<li>Unaffected sibling of affected individual: 2 in 3 (~66.6%) \r\n<li>Aunt or uncle of affected individual: 1 in 2 (50%) \r\n<li>First cousin of affected individual: 1 in 4 (25%)</li></ul>\r\n<p>If someone has carrier testing and is found to be negative (not a carrier), that person's children are typically assumed to be negative also.<br><br>More information about the use of genetic carrier testing is available on GeneTests' Web site and can be viewed by clicking <a href=\"http://www.ncbi.nlm.nih.gov/projects/GeneTests/static/concepts/primer/primerusesof.shtml#carrier\" target=_blank>here</a>.<br><br>Individuals who are interested in learning about genetic testing and about their specific risk to be a carrier should speak with a genetics professional.</p>","dateModified":"2012-06-28T10:57:00","resourceClassificationName":"Diagnosis","references":[]},{"questionId":2567,"questionText":"How can I find a genetics professional in my area?","answerText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by  the <a href=\"https://www.acmg.net/ACMG/Find_Genetic_Services/ACMG/ISGweb/FindaGeneticService.aspx?hkey=720856ab-a827-42fb-a788-b618b15079f9\" target=\"_blank\">American College of Medical Genetics</a>&nbsp;and the&nbsp;<a href=\"https://www.findageneticcounselor.com/\" target=\"_blank\">National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also <a href=\"http://ghr.nlm.nih.gov/handbook/consult?show=all\" target=\"_blank\">learn more about genetic consultations</a> from Genetics Home Reference.","dateModified":"2017-12-06T00:00:00","references":[]}]},{"caseId":35089,"abbreviatedInquiry":"We found out my cousin has metachromatic leukodystrophy about 8 months ago. He has the adult form. He was having some problems about a year before we found out. I was wondering how long he might have to live and how bad the disease will get over time.","caseQuestions":[{"questionId":6193,"questionText":"What is the prognosis for individuals with metachromatic leukodystrophy?","answerText":"The prognosis for metachromatic leukodystrophy (MLD) is poor.[5223] The late infantile&nbsp;form of the disorder, the most common type, usually appears in the second year of life. This form typically progresses over approximately 5 to 10 years.[5224] Most children with the infantile form die by age 5.[5223] The juvenile form, with onset between the age of 4 and adolescence, has a slower progression than the late infantile form and symptoms may develop over 10 to 20 years; death typically occurs 10 to 20 years following onset.[5223][5224] In the adult form, the first symptoms typically&nbsp;appear during the teenage years or later. This form may possibly progress over 20 to 30 years, although many individuals with the adult form die within 6 to 14 years following the onset of symptoms.[5223][5224] During the progression of this form there may be some periods of relative stability and other periods of more rapid decline.[5224]","dateModified":"2012-05-09T11:41:00","resourceClassificationName":"Prognosis","references":[{"referenceId":5223,"authors":"","articleTitle":"Metachromatic Leukodystrophy Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders and Stroke (NINDS)","date":"June 22, 2018","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Metachromatic-Leukodystrophy-Information-Page","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5224,"authors":"","articleTitle":"Metachromatic leukodystrophy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"September 2007","url":"http://ghr.nlm.nih.gov/condition/metachromatic-leukodystrophy","dateAccessed":"2012-05-09T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13714,"phenoTypeName":"Abnormal enzyme/coenzyme activity","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":1637,"phenoTypeName":"Periventricular leukomalacia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10117,"phenoTypeName":"Abnormality of visual evoked potentials","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14146,"phenoTypeName":"Decreased nerve conduction velocity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5154,"phenoTypeName":"Developmental regression","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11434,"phenoTypeName":"Frequent falls","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11303,"phenoTypeName":"Hearing impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14625,"phenoTypeName":"Hyperintensity of cerebral white matter on MRI","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8725,"phenoTypeName":"Hyporeflexia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4328,"phenoTypeName":"Increased CSF protein","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3425,"phenoTypeName":"Infantile muscular hypotonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5588,"phenoTypeName":"Muscle spasm","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9419,"phenoTypeName":"Muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":2230,"phenoTypeName":"Peripheral neuropathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13862,"phenoTypeName":"Progressive spasticity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5614,"phenoTypeName":"Visual impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14595,"phenoTypeName":"Addictive behavior","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13777,"phenoTypeName":"Bowel incontinence","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9421,"phenoTypeName":"Dystonia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6009,"phenoTypeName":"Emotional lability","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2826,"phenoTypeName":"Gastrostomy tube feeding in infancy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":461,"phenoTypeName":"Limb pain","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14143,"phenoTypeName":"Personality changes","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6006,"phenoTypeName":"Psychosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11835,"phenoTypeName":"Schizophrenia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":383,"phenoTypeName":"Toe walking","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6356,"phenoTypeName":"Urinary incontinence","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8119,"phenoTypeName":"Abnormal duodenum morphology","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13589,"phenoTypeName":"Abnormal stomach morphology","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":11519,"phenoTypeName":"Decerebrate rigidity","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":1836,"phenoTypeName":"Hemobilia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13756,"phenoTypeName":"Intussusception","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":6920,"phenoTypeName":"Neoplasm of the gallbladder","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14295,"phenoTypeName":"Abnormality of the cerebral white matter","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":13598,"phenoTypeName":"Babinski sign","percentRanges":"-"},{"phenoTypeId":9377,"phenoTypeName":"Bulbar palsy","percentRanges":"-"},{"phenoTypeId":9345,"phenoTypeName":"Cholecystitis","percentRanges":"-"},{"phenoTypeId":13706,"phenoTypeName":"Chorea","percentRanges":"-"},{"phenoTypeId":13990,"phenoTypeName":"Delusions","percentRanges":"-"},{"phenoTypeId":13565,"phenoTypeName":"EMG: neuropathic changes","percentRanges":"-"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","percentRanges":"-"},{"phenoTypeId":15061,"phenoTypeName":"Gallbladder dysfunction","percentRanges":"-"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","percentRanges":"-"},{"phenoTypeId":14131,"phenoTypeName":"Hallucinations","percentRanges":"-"},{"phenoTypeId":10649,"phenoTypeName":"Hyperreflexia","percentRanges":"-"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","percentRanges":"-"},{"phenoTypeId":6355,"phenoTypeName":"Loss of speech","percentRanges":"-"},{"phenoTypeId":8727,"phenoTypeName":"Mental deterioration","percentRanges":"-"},{"phenoTypeId":8716,"phenoTypeName":"Muscular hypotonia","percentRanges":"-"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","percentRanges":"-"},{"phenoTypeId":11164,"phenoTypeName":"Peripheral demyelination","percentRanges":"-"},{"phenoTypeId":13453,"phenoTypeName":"Progressive peripheral neuropathy","percentRanges":"-"},{"phenoTypeId":14300,"phenoTypeName":"Spastic tetraplegia","percentRanges":"-"},{"phenoTypeId":5204,"phenoTypeName":"Tetraplegia","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Metachromatic_leukodystrophy"}